论文部分内容阅读
目的探讨直肠癌术后应用注射用奥沙利铂为主联合化疗的临床疗法。方法选择江苏宿迁市泗洪县人民医院肿瘤科2012年1月至2013年1月所收治的行低位直肠癌保肛术后患者38例,随机将所有患者分为两组,分别是注射用奥沙利铂组(22例)和对照组(16例)。结果治疗组的复发率明显低于对照组,而3年生存率及总有效率均明显高于对照组差异有统计学意义(P<0.05)。两组患者均存在着一定的不良反应,但没有由于不良反应而造成治疗中止的患者,两组患者的不良反应发生率不存在明显性差异(P>0.05)。结论直肠癌术后应用注射用奥沙利铂为主联合化疗的临床疗效较佳,安全有效,不良反应少,是一种较理想的治疗方案。
Objective To investigate the clinical application of oxaliplatin-based combination chemotherapy for postoperative rectal cancer. Methods Suhong City Suqian County People’s Hospital Department of Oncology January 2012 to January 2013 were admitted to the line of low rectal cancer after anal sphincter preservation surgery in 38 patients, all patients were randomly divided into two groups, namely, injection of Austrian Salivatin group (22 cases) and control group (16 cases). Results The recurrence rate of the treatment group was significantly lower than that of the control group, but the 3-year survival rate and total effective rate were significantly higher than the control group (P <0.05). There were some adverse reactions in both groups. However, there was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). However, there was no discontinuation due to adverse reactions. Conclusion Postoperative application of oxaliplatin injection for rectal cancer combined with chemotherapy is better, safe and effective, with fewer adverse reactions, which is an ideal treatment.